Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vascular Therapies

Request full access

Vascular Therapies develops a drug-device combination product for perivascular implantation during arteriovenous fistula surgeries

Cresskill, United StatesFounded 2001Biotech & Life Sciences

About Vascular Therapies

Vascular Therapies, Inc. is a privately-held, clinical-stage biopharmaceutical company established in 2001. The company is focused on developing solutions to improve outcomes for patients with kidney and vascular diseases by addressing surgical stenosis. Since its inception, the company has secured approximately $124 million in funding over 14 rounds, with its first round in October 2005 and its latest in March 2022, attracting both existing and new investors, including a Fortune 100 global healthcare company.

The company's core focus is the development of Sirogen™, an investigational, proprietary formulation of the drug sirolimus designed for local, perivascular delivery during surgery. This product is delivered via a biodegradable collagen implant placed at the surgical site. The primary application for Sirogen™ is to enhance the outcomes of arteriovenous fistula (AVF) creation, a common procedure for patients with end-stage renal disease who require hemodialysis. AVF failure rates are a significant clinical challenge, and Sirogen™ aims to improve fistula maturation and long-term viability by reducing the stenosis that can occur where the vein and artery are connected.

Vascular Therapies is advancing Sirogen™ through rigorous clinical trials. The initial Phase 3 study, ACCESS, did not meet its primary endpoint; however, a subsequent analysis of a subgroup of patients aged 65 and older showed promising results in AVF maturation and durability. This led to the design of a second Phase 3 trial, ACCESS 2, a multinational, randomized study to validate these findings. Enrollment for the ACCESS 2 study, involving 136 patients across the US and UK, was completed in August 2024, with results anticipated in the second quarter of 2025. The Sirogen™ development program has received Fast Track status and Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for dialysis vascular access indications.

The company is led by CEO John McDermott, who brings nearly three decades of experience from the vascular industry, and founder Dr. Sriram Iyer, who serves as the Chief Scientific Officer. Vascular Therapies operates in the biopharmaceutical and drug delivery market, specifically targeting the unmet needs within the hemodialysis and vascular surgery sectors. Its business model centers on the research, development, and eventual commercialization of Sirogen™ upon receiving regulatory approval, thereby offering a therapeutic solution rather than a medical device to improve surgical outcomes for a high-risk patient population.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
29.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Medical Devices
Sector
Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Mar 2022 $25M $100M Undisclosed ↗
LATE VCOther financing Jan 2020 $17M $69M Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Vascular Therapies website traffic

Latest recorded traffic for Vascular Therapies is 160 monthly website visits, down 91.6% over the last three months. Vascular Therapies's team grew 0% over the past year.

Latest monthly visits160 3-month web change-91.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
CollplantRegenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing Ness Ziona, Israel Operational 48 $18M $4.8M
Rivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health Charlottesville, United States Operational
Vero BiotechAn emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions Atlanta, United States Operational
ImaginepharmaDeveloping therapies using its IMG-1 polypeptide for oral delivery, regenerative medicine, and novel therapeutics Pittsburgh, United States Low Activity
BiofourmisBiotechnology company that augments personalized care and therapies using digital therapeutics Boston, United States Operational
Cyfuse BiomedicalScaffold-free bio 3D printing for regenerative medicine Tokyo, Japan Operational
FreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine Barcelona, Spain Operational
Aderis PharmaceuticalsAderis Pharmaceuticals focused on discovery, development and commercialization of products for the diagnosis Hopkinton, United States Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vascular Therapies in the Cresskill ecosystem

Live from Dealroom

The Vascular Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • US Department of Health and Human Services

Series B and later1 investor entered at this stage

  • CNF Investments LLC
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vascular Therapies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vascular Therapies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.